What is Compounding?
Compounding is the practice of creating customized medications by combining, mixing, or altering ingredients to meet individual patient needs. For peptides, this often means preparing specific dosages or formulations not commercially available.
Types of Compounding Facilities
503A Traditional Compounding Pharmacies
Licensed under Section 503A of the Federal Food, Drug, and Cosmetic Act:
- Prepare medications for individual patients with prescriptions
- Primarily regulated by state boards of pharmacy
- Cannot compound "essentially copies" of commercial drugs
- Must use ingredients from FDA-approved sources or the bulk drug list
- Limited distribution (patient-specific)
503B Outsourcing Facilities
Registered under Section 503B, with FDA oversight:
- Can compound without patient-specific prescriptions
- Subject to FDA inspections and cGMP requirements
- May distribute to healthcare facilities
- Must report adverse events to FDA
- Stricter quality standards than 503A pharmacies
Bulk Drug Substance List
The FDA maintains lists of substances that can be used in compounding:
Category 1 (Approved for Compounding)
| Substance | 503A Status | 503B Status |
|---|---|---|
| Thymosin Alpha-1 | Permitted | Under Review |
| Glutathione | Permitted | Permitted |
Nominated but Not Yet Evaluated
Many peptides have been nominated for the bulk drug list but remain under FDA review:
- BPC-157
- Thymosin Beta-4 (TB-500)
- Various GHRPs and GHRHs
- Melanotan peptides
GLP-1 Compounding Controversy
The compounding of GLP-1 agonists like semaglutide has become a major regulatory issue:
Drug Shortage Exception
- When a drug is on the FDA shortage list, compounding may be permitted
- Semaglutide was on shortage list, allowing compounding
- Tirzepatide similarly affected
- When shortage ends, compounding must cease
Current Status (2024)
- FDA has issued warnings to compounders
- Salt form debate (semaglutide sodium vs. base)
- Many pharmacies continue under legal challenge
- Patient access significantly impacted
Compounding Requirements
For 503A Pharmacies
- Valid prescription required
- Licensed pharmacist supervision
- State pharmacy board compliance
- Appropriate labeling and beyond-use dating
- Quality testing (varies by state)
For 503B Facilities
- FDA registration required
- Current Good Manufacturing Practices (cGMP)
- Regular FDA inspections
- Adverse event reporting
- Comprehensive quality testing
- Proper labeling including facility name
Prohibited Practices
Both 503A and 503B compounders cannot:
- Compound drugs that are "essentially copies" of commercial products (when commercially available)
- Use ingredients on the FDA's "difficult to compound" list
- Use ingredients presenting safety concerns
- Make false or misleading claims
- Compound controlled substances without proper DEA registration
State vs. Federal Regulation
Compounding regulation involves both state and federal oversight:
- State Boards: License pharmacies, set practice standards
- FDA: Oversees 503B facilities, can take action against unsafe practices
- DEA: Regulates controlled substance compounding
- States may have stricter requirements than federal law
Finding a Compounding Pharmacy
When seeking compounded peptides:
- Verify state license and good standing
- For 503B, check FDA registration status
- Ask about quality testing and COAs
- Confirm they use appropriate ingredients
- Ensure proper prescription process
Recent Regulatory Updates
- 2024: FDA enforcement against GLP-1 compounders intensifies
- 2023: New guidance on 503B facility inspections
- 2022: Updates to bulk drug substance nomination process